Education
About Us
Working with TipRanks
Follow Us
Rapid Therapeutic Science Laboratories (RTSL)
OTHER OTC:RTSL
Total Valuation
Rapid Therapeutic Science Laboratories has a market cap or net worth of $52.99K. The enterprise value is $3.50M.
Market Cap$52.99K
Enterprise Value$3.50M
Share Statistics
Rapid Therapeutic Science Laboratories has 8,832,251 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,832,251
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Rapid Therapeutic Science Laboratories’s return on equity (ROE) is 0.54 and return on invested capital (ROIC) is -173.00%.
Return on Equity (ROE)0.54
Return on Assets (ROA)-0.75
Return on Invested Capital (ROIC)-173.00%
Return on Capital Employed (ROCE)0.47
Revenue Per Employee0.00
Profits Per Employee-598.24K
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Rapid Therapeutic Science Laboratories is ―. Rapid Therapeutic Science Laboratories’s PEG ratio is 0.06.
PE Ratio―
PS Ratio0.00
PB Ratio-1.85
Price to Fair Value-1.85
Price to FCF-4.88
Price to Operating Cash Flow-0.10
PEG Ratio0.06
Income Statement
In the last 12 months, Rapid Therapeutic Science Laboratories had revenue of 0.00 and earned -1.69M in profits. Earnings per share was -0.22.
Revenue0.00
Gross Profit0.00
Operating Income-1.26M
Pretax Income-1.79M
Net Income-1.69M
EBITDA-1.24M
Earnings Per Share (EPS)-0.22
Cash Flow
In the last 12 months, operating cash flow was -566.60K and capital expenditures -249.59K, giving a free cash flow of -816.19K billion.
Operating Cash Flow-566.60K
Free Cash Flow-816.19K
Free Cash Flow per Share-0.09
Dividends & Yields
Rapid Therapeutic Science Laboratories pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-5.34
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Rapid Therapeutic Science Laboratories upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Rapid Therapeutic Science Laboratories as a current ratio of 0.05, with Debt / Equity ratio of -111.75%
Current Ratio0.05
Quick Ratio0.01
Debt to Market Cap0.59
Net Debt to EBITDA-3.09
Interest Coverage Ratio-0.67
Taxes
In the past 12 months, Rapid Therapeutic Science Laboratories has paid -100.92K in taxes.
Income Tax-100.92K
Effective Tax Rate0.06
Enterprise Valuation
Rapid Therapeutic Science Laboratories EV to EBITDA ratio is -7.78, with an EV/FCF ratio of -8.10.
EV to Sales0.00
EV to EBITDA-7.78
EV to Free Cash Flow-8.10
EV to Operating Cash Flow-8.37
Balance Sheet
Rapid Therapeutic Science Laboratories has $2.16K in cash and marketable securities with $3.79M in debt, giving a net cash position of -$3.78M billion.
Cash & Marketable Securities$2.16K
Total Debt$3.79M
Net Cash-$3.78M
Net Cash Per Share-$0.43
Tangible Book Value Per Share-$0.43
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Rapid Therapeutic Science Laboratories is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―